UNSPSC 51342504: Telbivudine

This classification denotes a reverse transcriptase inhibitor with the molecular formula C10H14N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2OC4HKD3SF, chemically known as 2,4(1h,3h)-pyrimidinedione, 1-(2-deoxy-b-l-erythro-pentofuranosyl)-5-methyl- but generally known as telbivudine, which bears US NIH Compound Identifier 159269. European Medicines Agency schedules Telbivudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25231.

UNSPSC 51342504 Telbivudine, a Commodity code, does not align with the recent state and local solicitations tagged under it. The code nominally refers to a single antiviral pharmaceutical product; however, the recent opportunities record show purchases of naloxone, safe drug deactivation systems, medical and first aid supplies for emergency response, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and exploratory procurement for direct-to-manufacturer prescription programs. None of these solicitations involve telbivudine specifically, and the opportunities span medical supplies, emergency-response consumables, and pharmaceutical distribution rather than a single drug product. The issuing bodies include a county health department (Seminole County, Florida), a state health and human services agency (Texas HHS Commission), a city fire department (City of Tampa), and a multistate cooperative purchasing alliance (Minnesota MMCAP). The code shows little relevant recent activity aligned to its nominal scope.

Geographic activity appears concentrated in Florida, Texas, and Minnesota based on the four recent postings, with MMCAP's cooperative model extending reach across multiple states including Oregon. Representative recent opportunities include Seminole County's IFB 60459723LAS for naloxone and drug deactivation systems with a July 26, 2023 response deadline, the City of Tampa's IFB 26P00145 for medical and first aid supplies to the Fire Department Rescue Division with a March 13, 2026 deadline and $700,000 estimated contract value (designated as a sheltered Small Local Business Enterprise opportunity with a 5% bid discount), and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 proposal deadline. The Texas HHS Commission's April 2026 RFI HHS0017013 represents exploratory market research into direct-to-manufacturer prescription fulfillment without formal competitive timelines. Practitioners evaluating this code should verify whether telbivudine procurement activity exists outside these four records or consider whether the tagging reflects a data classification misalignment.